• HIGHLIGHTS
============

\- Alpha 1-blocker is effective in the treatment of female lower urinary tract symptoms. It showed significant symptom relief compared to placebo, however there was no differences in maximal flow rate and postvoid residual between the α1-blocker and placebo groups.

INTRODUCTION
============

The European Urological Association guidelines suggest that, relative to placebo, alpha-1 adrenergic receptor blockers (α1-blockers) reduce urinary symptoms and increase maximal flow rate (Qmax) in men with lower urinary tract symptoms (LUTS) \[[@b1-inj-1836188-094]\]. These agents increase smooth muscle relaxation in the prostate and bladder neck. They constitute the first-line drug treatment of male LUTS due to their rapid onset of action, satisfactory efficacy, and acceptable safety profiles.

Voiding dysfunction in women is defined by the International Continence Society and International Urogynecological Association as abnormally slow and/or incomplete urination diagnosed based on symptoms and urodynamic studies \[[@b2-inj-1836188-094]\]. The overall prevalence of female voiding dysfunction is estimated to be between 3% and 39% \[[@b3-inj-1836188-094],[@b4-inj-1836188-094]\]. However, considering the present lack of standardized diagnostic criteria and clinical guidelines, female LUTS is likely overlooked and underestimated. Moreover, the pathophysiological mechanism of female LUTS remains unclear \[[@b5-inj-1836188-094]\].

Although not officially registered for the treatment of female LUTS \[[@b6-inj-1836188-094]\], α1-blockers have been used to alleviate LUTS in women based on their presumed activity in the relief of functional bladder outlet obstruction \[[@b7-inj-1836188-094]\]. In part, the current use of α1-blockers for female LUTS is based on their remarkable effects in the treatment of male LUTS \[[@b8-inj-1836188-094]\]. Published clinical trials evaluating the use of α1-blockers for female LUTS have remained limited in prevalence and participation and have produced contradictory results. The lack of well-designed randomized clinical trials (RCTs) further limits meaningful conclusions. Thus, the authors in the present study conducted a systematic review and meta-analysis assessing the effect of α1-blockers on female LUTS to address some of the current controversies and to obtain additional statistical information.

MATERIALS AND METHODS
=====================

This systematic review was registered in PROSPERO (CRD42 018096181).

Search Strategy
---------------

The authors in the present study conducted computerized bibliographic searches of the PubMed/MEDLINE, Embase, and Cochrane Library databases up to April 2018. The search terms included "female or women," "alpha blocker," "lower urinary tract symptoms," "overactive bladder," "bladder outlet obstruction," "urinary incontinence," and relevant variants. Conference and meeting abstracts were excluded even if they otherwise met the eligibility criteria. The searches identified 482 candidate articles. Two authors (DKK and YSH) independently reviewed the titles and abstracts based on the inclusion criteria and subsequently reviewed the identified articles.

Trial Inclusion Criteria and Exclusion Criteria
-----------------------------------------------

Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the eligibility of each study was evaluated using the PICOS (participants, interventions, comparators, outcomes, and study design) method \[[@b9-inj-1836188-094]\]. The authors in the present study defined the study population as female patients with a clinical diagnosis of LUTS and the intervention as α1-blocker treatment. Where appropriate, the placebo was defined as the comparator. The following outcomes were analyzed: urinary symptom score (International Prostate Symptom Score \[IPSS\] or American Urological Association Symptom Score \[AUASS\]), Qmax, and postvoid residual (PVR) urine volume. The inclusion criteria were: RCT or prospective design, nonanimal research, female patients with a clinical diagnosis of LUTS, use of α1-blockers, and reported values for IPSS or AUASS scores, Qmax, and PVR urine volume.

The exclusion criteria were: retrospective design, the combination of α1-blockers with other drugs (e.g., anticholinergics or M-cholinolytics), and studies including only elderly women (mean age \>70 years).

Data Extraction
---------------

Two authors (DKK and YSH) reviewed the full articles and extracted the data from each study independently. Any conflicts in the extracted data were resolved through consensus. The extracted data included study design details, inclusion and exclusion criteria, randomization, participant demographics, treatment characteristics (regimen, dosage, and duration), measured outcomes (IPSS or AUASS, Qmax, and PVR urine volume), and results (mean difference \[MD\] and standard deviation \[SD\]).

Assessment of Study Quality
---------------------------

The design and implementation of RCTs were assessed for the risk of bias according to recent meta-analysis guidelines \[[@b10-inj-1836188-094],[@b11-inj-1836188-094]\]. The risk of bias assessment included examination of the use of random sequence generation, allocation concealment, blinding of participants and researchers, blinding of outcome assessment, incomplete outcome data, and selective reporting. For prospective studies, the quality of the included clinical trials was evaluated according to the methodological index of the Downs and Black scale using 5 major assessment categories: reporting, external validity, bias, confounding, and power \[[@b12-inj-1836188-094]\].

The authors of the present study evaluated the certainty of comparisons using the Grading of Recommendations, Assessments, Developments, and Evaluation (GRADE) system, which provides a systematic approach to the evaluation of the quality of evidence and strength of recommendations \[[@b10-inj-1836188-094]\] through assessments of the following criteria: methodology, precision, consistency, directness, and risk of publication bias. Based on these criteria, the authors in the present study assessed only direct evidence of pairwise meta-analysis by classifying the quality of evidence on a 4-level scale as high, moderate, low, and very low.

Statistical Analysis
--------------------

Changes in LUTS outcomes were measured by IPSS or AUASS, Qmax, and PVR urine volume values, which were recorded as continuous data. Mean and SD values were extracted from all studies except for that published by Lee et al. \[[@b5-inj-1836188-094]\], which presented the results as median and interquartile range. The authors in the present study subsequently calculated the mean and SD values using a known statistical method \[[@b13-inj-1836188-094],[@b14-inj-1836188-094]\]. Pooled MDs for pre- and posttreatment values and 95% confidence intervals (CIs) were calculated for continuous variables. For RCTs, pooled MDs for treatment and placebo group values were calculated along with 95% CIs. Adverse events were compared between α1-blocker and placebo groups using pooled odd ratios (ORs) for dichotomous data across studies. The meta-analyses were performed using the random-effects model of DerSimonian and Laird to obtain pooled overall MDs with 95% CIs for outcomes \[[@b15-inj-1836188-094]\].

Statistical heterogeneity was assessed using the I^2^ value and the chi-square test. A Cochran Q statistic P\<0.05 or I^2^\>50% indicated the presence of statistically significant heterogeneity. The authors in the present study assessed the stability of the results by sequentially excluding each included study as a sensitivity analysis.

Funnel plots and the Egger test were used to evaluate small-study effects, with more than 10 studies included in the analysis. A comprehensive meta-analysis was conducted to investigate potential publication bias. The results are displayed using a funnel plot, with the study size shown on the y-axis as a function of the effect size on the x-axis. Symmetry reversal funnel diagrams did not show significant publication bias, which is indicated by distortion and asymmetry of the inverted funnel plots. P-values\<0.05 from the Egger test signaled statistically significant publication bias.

The meta-analysis was performed using Review Manager v.5.1 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark, 2008). All P-values were 2-sided, and, except for the test of discrepancy, P-values\<0.05 were considered to indicate a statistically significant result.

RESULTS
=======

Systematic Review Process
-------------------------

The authors in the present study used the PRISMA framework to analyze and summarize our systematic analysis and meta-review process ([Fig. 1](#f1-inj-1836188-094){ref-type="fig"}). Only published studies were included to minimize publication bias. The initial database searches identified 482 articles, which were reduced to 406 following duplicate removal. Subsequently, title and abstract review eliminated 377 articles, with only trials published in English included in the present study. An analysis of the remaining full-text articles with respect to the inclusion criteria resulted in the final selection of 14 studies ([Table 1](#t1-inj-1836188-094){ref-type="table"}) with a total of 1,319 patients \[[@b5-inj-1836188-094],[@b6-inj-1836188-094],[@b16-inj-1836188-094]-[@b27-inj-1836188-094]\]. Of these studies, 6 were RCTs and 8 were open-label prospective studies. The α1-blockers used in these studies included alfuzosin, tamsulosin, and terazosin. The duration of treatment ranged from 4 to 12 weeks across all studies. In all publications, urinary symptom scores were assessed using the IPSS or AUASS. These 2 questionnaires consist of the same 9 questions about incomplete emptying, frequency, intermittency, urgency, weak stream, straining, nocturia, and quality of life due to urinary symptoms ([Supplementary Figs. 1](#SD1-inj-1836188-094){ref-type="supplementary-material"}, [2](#SD2-inj-1836188-094){ref-type="supplementary-material"}).

Comparisons of Pretreatment and Posttreatment Outcomes
------------------------------------------------------

Subgroup analyses were performed by study design and type of α1-blocker ([Fig. 2](#f2-inj-1836188-094){ref-type="fig"}, [Supplementary Fig. 3](#SD3-inj-1836188-094){ref-type="supplementary-material"}).

### Urinary symptom score

Urinary symptoms score was analyzed in 9 studies with 879 patients ([Fig. 2A](#f2-inj-1836188-094){ref-type="fig"}). Posttreatment outcomes demonstrated statistically significant symptom relief relative to pretreatment (MD, -5.85; 95% CI, -7.71 to -3.99, P\<0.00001). Heterogeneity was observed among the included studies (I^2^=89%; P\<0.00001).

### Qmax

The analysis of Qmax comprised 13 studies with 1,003 patients ([Fig. 2B](#f2-inj-1836188-094){ref-type="fig"}). Qmax significantly increased following treatment (MD, 3.67 mL/sec; 95% CI, 2.76--4.59 mL/sec, P\<0.00001). Heterogeneity among the included studies was observed (I^2^=72%; P\<0.0001).

### PVR volume

PVR volume was assessed on the basis of 12 studies with 938 patients ([Fig. 2C](#f2-inj-1836188-094){ref-type="fig"}). Posttreatment PVR values significantly decreased relative to pretreatment values (MD, -28.46 mL; 95% CI, -34.99 to -21.93 mL; P\<0.00001). Statistical heterogeneity was not observed (I^2^=47%; P=0.04).

Outcome Comparisons Between Α1-Blocker and Placebo Groups
---------------------------------------------------------

### Urinary symptom score

Urinary symptoms score was analyzed in 4 studies with 396 patients ([Fig. 3A](#f3-inj-1836188-094){ref-type="fig"}). Statistically significant symptom relief was observed following α1-blocker treatment relative to placebo (MD, -1.60; 95% CI, -2.68 to -0.51; P=0.004). Between-study heterogeneity was observed (I^2^=68%; P=0.03).

### Qmax

The analysis of Qmax comprised 4 studies with 396 patients ([Fig. 3B](#f3-inj-1836188-094){ref-type="fig"}). Treatment with α1-blockers did not significantly alter Qmax relative to placebo (MD, 0.05 mL/sec; 95% CI, -0.75 to 0.83 mL/sec; P=0.91). Heterogeneity among the included studies was not observed (I^2^=0%; P=0.50).

### PVR volume

PVR volume was analyzed on the basis of 2 studies with 234 patients ([Fig. 3C](#f3-inj-1836188-094){ref-type="fig"}). No significant difference in PVR volume was observed between the α1-blocker and placebo groups (MD, -8.10 mL; 95% CI, -32.32 to 16.12 mL; P=0.51). Between-study heterogeneity was observed (I^2^=91%; P=0.001).

### Adverse events

Adverse events were reported in 4 studies with 403 patients ([Fig. 3D](#f3-inj-1836188-094){ref-type="fig"}). No significant difference in adverse events was observed between the α1-blocker and placebo groups (OR, 1.69; 95% CI, 0.56-5.08, P=0.35). Between-study heterogeneity was observed (I^2^=68%; P=0.02).

Sensitivity Analysis
--------------------

A sensitivity analysis was performed using sequential exclusion of studies to evaluate the effect of each study on the overall results of the meta-analysis. The exclusion of any single study did not result in statistically significant changes in the results (data not shown). The results were statistically reliable.

Publication Bias, Quality Assessment, and Qualitative Risk of Bias
------------------------------------------------------------------

The funnel plot analysis of publication bias of the pre-post studies demonstrated a certain degree of symmetry ([Fig. 4](#f4-inj-1836188-094){ref-type="fig"}). The Egger test revealed no statistical evidence of publication bias in the meta-analysis of Qmax and PVR volume (P=0.77 and P=0.18, respectively).

The Downs and Black scale was utilized to assess the quality of 8 prospective trials using the reporting, external validity, bias, confounding, and power assessment categories ([Table 2](#t2-inj-1836188-094){ref-type="table"}). The Downs and Black scores of the evaluated studies ranged from 12 to 15. The risk of bias graph and assessment of RCTs are summarized in [Figs. 5](#f5-inj-1836188-094){ref-type="fig"} and [6](#f6-inj-1836188-094){ref-type="fig"}. One study did demonstrate a statistically high risk of other biases (early stop due to low recruitment and enrollment rate).

The results of the GRADE quality assessment for direct evidence of each comparison are shown in [Tables 3](#t3-inj-1836188-094){ref-type="table"}-[](#t4-inj-1836188-094){ref-type="table"}[5](#t5-inj-1836188-094){ref-type="table"}. Of the 10 comparisons, certainty was moderate in 5 and low in 5.

DISCUSSION
==========

Large-population studies have indicated that LUTS are highly prevalent in women and men over 40 years of age \[[@b28-inj-1836188-094]\]. Storage LUTS, including urinary incontinence, are more prevalent in women. Conversely, voiding LUTS are more common in men. However, women also suffer from voiding LUTS despite the absence of obvious anatomic obstructions, such as benign prostatic obstructions seen in men. In men with benign prostatic hyperplasia, α1-blockers relieve LUTS via smooth muscle relaxation in the prostate and the bladder neck. Thus, many clinicians have prescribed similar treatments to women with LUTS based on the assumption that α1-blockers will similarly affect the female bladder neck. Some open-label prospective trials \[[@b16-inj-1836188-094]-[@b19-inj-1836188-094],[@b21-inj-1836188-094],[@b23-inj-1836188-094],[@b24-inj-1836188-094],[@b27-inj-1836188-094]\] and RCTs \[[@b5-inj-1836188-094],[@b6-inj-1836188-094],[@b20-inj-1836188-094],[@b22-inj-1836188-094],[@b25-inj-1836188-094],[@b26-inj-1836188-094]\] have examined the effect of α1-blockers on female voiding dysfunction. However, the outcomes of these studies have not been consistent. The lack of well-designed RCTs with large study populations further prevents the establishment of a consensus on the use of α1-blockers for LUTS in women. Therefore, the authors in the present study performed a systematic review and meta-analysis to assess the evidence and to provide more information regarding the efficacy of α1-blockers in the treatment of female LUTS.

Our meta-analysis demonstrated that α1-blockers have beneficial effects on female LUTS. Our study comprised 2 analyses: a comparison of urinary symptom scores and urodynamic parameters before and after α1-blocker treatment in 8 prospective, open-label studies and 5 RCTs, and the comparison of the same variables following α1-blocker and placebo treatments in 4 RCTs. The first analysis indicated that α1-blockers are effective in reducing urinary symptom scores (-5.85 points), increasing Qmax (+3.67 mL/sec), and decreasing PVR urine volume (-28.46 mL). Recent studies have suggested that α1-blockers may provide an effective treatment effect for female functional bladder outlet obstruction. Kumar et al. \[[@b29-inj-1836188-094]\] reported that 50% of women with functional bladder outlet obstruction experienced improvements in urinary symptoms, Qmax, and PVR after treatment with α1-blocker therapy alone. Yamanish et al. \[[@b30-inj-1836188-094]\] also reported that female patients with detrusor underactivity showed improvements in the total IPSS (-6.3 points) and PVR volume (48 mL) after 4 weeks of α1-blocker treatment, and that storage and voiding symptom scores were reduced.

The second analysis demonstrated that α1-blockers are more effective in reducing urinary symptoms than placebo, but with an MD of only 1.6 points. Furthermore, no significant differences in Qmax and PVR volume between the α1-blocker and the placebo groups were observed. Zhang et al. \[[@b31-inj-1836188-094]\] previously performed a meta-analysis comparing the effects of tamsulosin and various controls (placebo, anticholinergics, or combination therapy) in female LUTS patients. Our meta-analysis included studies using not only tamsulosin, but also other α1-blockers, such as alfuzosin and terazosin. In addition, only placebo control arms were included in our analysis. Furthermore, in contrast to Zhang and colleagues, the authors in the present study also added prospective open-label studies to compare pre- and posttreatment clinical variables in our analysis of the effects of α1-blockers on female LUTS.

Although our meta-analysis indicated positive effects of α1-blockers on both subjective and objective variables in the treatment of LUTS, we recommend caution in the interpretation of the results. Bias is likely in simple pre-post comparisons in clinical studies of voiding dysfunction. For example, as participants become accustomed to the test method (i.e., uroflowmetry), the results of the subsequent tests can improve. A strong behavioral factor has been observed in the placebo response of LUTS patients, as revealed by voiding diaries that make patients aware of their voiding habits, as well as of the timing and quantity of fluid intake \[[@b32-inj-1836188-094]\]. In addition, significant placebo effects cannot be avoided in open-label studies. Thus, the clinical implications of our pre-post study meta-analysis are limited.

In contrast, the second meta-analysis, targeting placebo-controlled RCTs, has more important clinical implications. This meta-analysis, which demonstrated a significant effect of α1-blockers on urinary symptom relief, suggests that α1-blockers should be considered for the treatment of women suffering from LUTS. However, a \<2-point MD in urinary symptom scores and an absence of significant differences in objective measurements were observed between the α1-blocker and placebo groups. These findings may be partly explained by the placebo effect. The involvement of neurotransmitters in the urination process can account for the LUTS placebo response, at least with respect to the subjective outcome. A placebo-induced dopamine release in LUTS patients has been hypothesized to improve bladder function \[[@b33-inj-1836188-094]\]. Several studies have examined the specific factors influencing the placebo response in LUTS patients. Placebo therapy rapidly produces a significant improvement in Qmax and relieves the symptoms of benign prostatic hyperplasia, with fading beneficial effects remaining even after 2 years \[[@b34-inj-1836188-094]\]. Another study also suggested that the placebo effect is often rapid, but declines over time \[[@b35-inj-1836188-094]\]. In the present meta-analysis, the treatment periods in the RCTs ranged from 4 to 12 weeks. Thus, it is possible that the peak placebo effect was observed in the urinary symptom score and Qmax measurements due to the short follow-up period. Nickel \[[@b34-inj-1836188-094]\] also demonstrated that placebo responses were higher in patients with small or normal prostates. Assuming that female LUTS are more similar to LUTS in men with smaller prostates, a stronger placebo effect in women may further explain the observed limited effect of α1-blockers on female LUTS.

The authors in the present study compared adverse event rates between α1-blockers and placebo in the studies that reported safety outcomes for the α1-blockers and found no statistically significant difference in the adverse event rate of the α1-blockers compared to placebo \[[@b5-inj-1836188-094],[@b6-inj-1836188-094],[@b25-inj-1836188-094],[@b26-inj-1836188-094]\]. The side effects of α1-blockers reported in the studies were dizziness, headache, asthenia, GI discomfort, and edema. The most common adverse events were dizziness and headache. Although the results of this study showed no difference in adverse events between α1-blockers and placebo, clinicians should always use caution regarding side effects while assessing a patient's condition.

Among the RCTs analyzed, Lee et al. \[[@b5-inj-1836188-094]\] applied relatively strict inclusion criteria (AUASS ≥15 and Qmax \<15 mL/sec and/or PVR volume \>150 mL). However, the other 3 RCTs used very simple selection criteria (IPSS\>8), with no specific cutoffs for Qmax or PVR volume \[[@b6-inj-1836188-094],[@b25-inj-1836188-094],[@b26-inj-1836188-094]\]. Such broad criteria may not select for α1-blocker-responsive candidates. The meta-analysis was further limited by the small sample sizes and the methodological quality of the included RCTs. Moreover, between-trial differences in α1-blockers and treatment periods also likely affected the results. Thus, high-quality RCTs, with large sample sizes, adequately defined study participants, and long-term treatment and follow-up, are required to overcome these limitations and to draw more reliable conclusions.

In conclusion, our results suggest that α1-blockers may be effective in the treatment of female LUTS. However, certain limitations of the study, which could have led to inevitable bias, may have masked the effects of α1-blockers in the treatment of female LUTS. Thus, the results of this study should be interpreted with caution. Although α1-blockers are effective for treating female LUTS patients, the effect of α1-blockers on female LUTS should be assessed according to the underlying cause. In addition, the role of α1-blockers in combination therapy with other drugs should also be investigated.
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SUPPLEMENTARY MATERIALS
=======================

Supplementary Figs. 1-3 can be found via <https://doi.org/10.5213/inj.1836188.094>.

![PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) flowchart. Chart presenting the flow of information through the different phases of the systematic review, together with the utilized exclusion criteria.](inj-1836188-094f1){#f1-inj-1836188-094}

![Forest plots comparing pre-post study outcomes (subgroup-analysis by study design). The evaluated outcomes included urinary symptom score (A), maximal flow rate (B), and postvoid residual urine volume (C). P, prazosin; T, terazosin; SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836188-094f2){#f2-inj-1836188-094}

![Forest plots comparing outcomes between α1-blocker and placebo groups. Evaluated outcomes included urinary symptom score (A), maximal flow rate (B), residual urine volume (C), and adverse events (D). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836188-094f3){#f3-inj-1836188-094}

![Publication bias analysis. Funnel plots for maximal flow rate (A) and postvoid residual urine volume (B).](inj-1836188-094f4){#f4-inj-1836188-094}

![Risk of bias assessment graph. Risk of bias was assessed using the Cochrane Risk of Bias Tool.](inj-1836188-094f5){#f5-inj-1836188-094}

![Study-specific bias risk. Risk of bias was assessed using the Cochrane Risk of Bias Tool. A green plus sign indicates a low risk of bias, a yellow question mark indicates an unclear risk of bias, and a red minus sign indicates a high risk of bias.](inj-1836188-094f6){#f6-inj-1836188-094}

###### 

Characteristics of the selected studies

  Study                                             Design                   No. of participants   Alpha-blocker dose (mg/day)   Treatment period   Comparator (mg/day)                    Mean age (yr)                                      Outcomes
  ------------------------------------------------- ------------------------ --------------------- ----------------------------- ------------------ -------------------------------------- -------------------------------------------------- -------------------
  Athanasopoulos, 2009 \[[@b16-inj-1836188-094]\]   Open-label prospective   25                    Alfuzosin 10 mg               8 Weeks            None                                   53                                                 Qmax, PVR
  Chang, 2006 \[[@b17-inj-1836188-094]\]            Open-label prospective   71                    Tamsulosin 0.2 mg             8 Weeks            None                                   54.4                                               IPSS, Qmax, PVR
  Chang, 2008 \[[@b18-inj-1836188-094]\]            Open-label prospective   97                    Tamsulosin 0.2 mg             6 Weeks            None                                   63.8                                               IPSS, Qmax, PVR
  Costantini, 2009 \[[@b19-inj-1836188-094]\]       Open-label prospective   63                    Tamsulosin 0.4 mg             ≥ 4 Weeks          None                                   60.2                                               Qmax, PVR
  Hajebrahimi, 2011 \[[@b20-inj-1836188-094]\]      RCT                      40                    Tamsulosin 0.4 mg             12 Weeks           Prazosin 1--2 mg                       Tamsulosin, 47.35; prazosin, 49.4                  Qmax, PVR
  Kim, 2011 \[[@b22-inj-1836188-094]\]              RCT                      181                   Tamsulosin 0.2 mg             12 Weeks           Tamsulosin 0.2 mg + tolterodine 2 mg   Tamsulosin, 52.2; tamsulosin + tolterodine, 53.7   IPSS, Qmax, PVR
  Kim, 2014 \[[@b21-inj-1836188-094]\]              Open-label prospective   296                   Tamsulosin 0.2 mg             4 Weeks            None                                   58.3                                               IPSS, Qmax, PVR
  Koh, 2011 \[[@b23-inj-1836188-094]\]              Open-label prospective   19                    Alfuzocin 10 mg               12 Weeks           None                                   50.4                                               IPSS, Qmax, PVR
  Lee, 2010 \[[@b24-inj-1836188-094]\]              Open-label prospective   106                   Tamsulosin 0.2 mg             8 Weeks            None                                   52.9                                               IPSS, Qmax, PVR
  Lee, 2018 \[[@b5-inj-1836188-094]\]               RCT                      154                   Alfuzosin 10 mg               8 Weeks            Placebo                                Alfuzosin, 57.4; placebo, 57.9                     AUA-SS, Qmax, PVR
  Lepor, 1995 \[[@b25-inj-1836188-094]\]            RCT                      29                    Terazosin 10 mg               6 Weeks            Placebo                                Terazosin, 60.6; placebo, 62.8                     AUA-SS, Qmax
  Low, 2008 \[[@b26-inj-1836188-094]\]              RCT                      80                    Terazosin 10 mg               14 Weeks           Placebo                                NA                                                 IPSS, Qmax, PVR
  Pischedda, 2005 \[[@b27-inj-1836188-094]\]        Open-label prospective   18                    Tamsulosin 0.4 mg             4 Weeks            None                                   49.9                                               Qmax, PVR
  Pummangura, 2007 \[[@b6-inj-1836188-094]\]        RCT                      140                   Tamsulosin 0.2 mg             4 Weeks            Placebo                                Tamsulosin, 42.5; placebo, 49.8                    IPSS, Qmax, PVR

Qmax, maximal flow rate; PVR, postvoid residual volume; IPSS, International Prostate Symptom Score; AUASS, American Urological Association Symptom Score; NA, not available; RCT, randomized clinical trial.

###### 

Downs and black scale for quality assessment of non-RCT and single-arm studies

  Study                                             Reporting   External validity   Internal validity   Power   Total   
  ------------------------------------------------- ----------- ------------------- ------------------- ------- ------- ----
  Athanasopoulos, 2009 \[[@b16-inj-1836188-094]\]   7           1                   3                   1       1       13
  Chang, 2006 \[[@b17-inj-1836188-094]\]            7           1                   4                   1       2       15
  Chang, 2008 \[[@b18-inj-1836188-094]\]            7           1                   3                   1       2       14
  Costantini, 2009 \[[@b19-inj-1836188-094]\]       7           1                   3                   1       2       14
  Kim, 2014 \[[@b21-inj-1836188-094]\]              5           1                   3                   1       2       12
  Koh, 2011 \[[@b23-inj-1836188-094]\]              7           1                   3                   1       1       13
  Lee, 2010 \[[@b24-inj-1836188-094]\]              7           1                   3                   1       2       14
  Pischedda, 2005 \[[@b27-inj-1836188-094]\]        6           1                   3                   1       1       12

RCT, randomized clinical trial.

###### 

Results of the GRADE quality assessment for evidence of comparisons between pretreatment and posttreatment outcomes

  No. of studies                 Study design                      Risk of bias   Inconsistency   Indirectness   Imprecision                                                 Other considerations   No. of patients   Effect, absolute (95% CI)   Certainty                                       Importance       
  ------------------------------ --------------------------------- -------------- --------------- -------------- ----------------------------------------------------------- ---------------------- ----------------- --------------------------- ----------------------------------------------- ---------------- ----------
  Urinary symptom score                                                                                                                                                                                                                                                                                            
  5                              Prospective, open-label studies   Not serious    Not serious     Not serious    Not serious                                                 None                   589               589                         MD, 4.7 lower; (7.17 lower to 2.23 lower)       ●●◯◯, Low        Critical
  4                              Randomized trials                 Not serious    Not serious     Not serious    Serious^[a)](#tfn1-inj-1836188-094){ref-type="table-fn"}^   None                   290               290                         MD, 7.37 lower; (10.62 lower to 4.12 lower)     ●●●◯, Moderate   Critical
  Maximal flow rate (mL/sec)                                                                                                                                                                                                                                                                                       
  7                              Prospective, open-label studies   Not serious    Not serious     Not serious    Not serious                                                 None                   676               676                         MD, 4.53 higher; (3.37 higher to 5.68 higher)   ●●◯◯, Low        Critical
  6                              Randomized trials                 Not serious    Not serious     Not serious    Serious^[a)](#tfn1-inj-1836188-094){ref-type="table-fn"}^   None                   327               327                         MD, 2.58 higher; (1.67 higher to 3.49 higher)   ●●●◯, Moderate   Critical
  Postvoid residual urine (mL)                                                                                                                                                                                                                                                                                     
  7                              Prospective, open-label studies   Not serious    Not serious     Not serious    Not serious                                                 None                   676               676                         MD, 32.79 lower; (43.72 lower to 21.87 lower)   ●●◯◯, Low        Critical
  5                              Randomized trials                 Not serious    Not serious     Not serious    Serious^[a)](#tfn1-inj-1836188-094){ref-type="table-fn"}^   None                   262               262                         MD, 27.73 lower; (34.14 lower to 21.33 lower)   ●●●◯, Moderate   Critical

GRADE, Grading of Recommendations, Assessments, Developments, and Evaluation; CI, confidence interval; OR, odds ratio; MD, mean difference.

Total number of participants was less than 400.

###### 

Results of the GRADE quality assessment for evidence of comparisons between alpha-1 blocker and placebo groups (treatment outcomes)

  No. of studies                 Study design        Risk of bias   Inconsistency   Indirectness   Imprecision                                                      Other considerations   No. of patients   Effect, absolute (95% CI)   Certainty                                       Importance       
  ------------------------------ ------------------- -------------- --------------- -------------- ---------------------------------------------------------------- ---------------------- ----------------- --------------------------- ----------------------------------------------- ---------------- ----------
  Urinary symptom score                                                                                                                                                                                                                                                                                   
  4                              Randomized trials   Not serious    Not serious     Not serious    Serious^[a)](#tfn2-inj-1836188-094){ref-type="table-fn"}^        None                   199               197                         MD, 1.60 lower; (2.68 lower to 0.51 lower)      ●●●◯, Moderate   Critical
  Maximal flow rate (mL/sec)                                                                                                                                                                                                                                                                              
  4                              Randomized trials   Not serious    Not serious     Not serious    Very serious^[b)](#tfn3-inj-1836188-094){ref-type="table-fn"}^   None                   199               197                         MD, 0.05 higher; (0.74 lower to 0.83 higher)    ●●◯◯, Low        Critical
  Postvoid residual urine (mL)                                                                                                                                                                                                                                                                            
  2                              Randomized trials   Not serious    Not serious     Not serious    Very serious^[b)](#tfn3-inj-1836188-094){ref-type="table-fn"}^   None                   119               115                         MD, 1.25 lower; (32.11 lower to 15.42 higher)   ●●◯◯, Low        Critical

GRADE, Grading of Recommendations, Assessments, Developments, and Evaluation; CI, confidence interval; OR, odds ratio; MD, mean difference.

Total number of participants was less than 400.

Estimate of effect includes both little and no effect.

###### 

Results of the GRADE quality assessment for evidence of comparison between alpha-1 blocker and placebo groups (adverse events)

  No. of studies   Study design        Risk of bias   Inconsistency   Indirectness   Imprecision                                                 Other considerations   No. of patients   Effect   Certainty                  Importance                                                   
  ---------------- ------------------- -------------- --------------- -------------- ----------------------------------------------------------- ---------------------- ----------------- -------- -------------------------- ------------------------------------------- ---------------- ----------
  Adverse events                                                                                                                                                                                                                                                                           
  4                Randomized trials   Not serious    Not serious     Not serious    Serious^[a)](#tfn4-inj-1836188-094){ref-type="table-fn"}^   None                   203               200      OR, 1.69; (0.56 to 5.08)   11 more per 100 (from 9 fewer to 38 more)   ●●●◯, Moderate   Critical

GRADE, Grading of Recommendations, Assessments, Developments, and Evaluation; CI, confidence interval; OR, odds ratio.

Estimate of effect includes both little and no effect.
